- Notified by the FDA that it has acknowledged receipt of its recently resubmitted NDA for Vitaros and considers it a complete, class 2 response to the Company's 2008 action letter
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.
Address
11975 El Camino Real Ste 300
SAN DIEGO, CA 92130-2543
United States
SAN DIEGO, CA 92130-2543
United States
Website
http://www.apricusbio.comKey stats and ratios
| Q2 (Jun '17) | 2016 | |
| Net profit margin | - | -128.98% |
| Operating margin | - | -232.64% |
| EBITD margin | - | -227.38% |
| Return on average assets | -97.50% | -119.11% |
| Return on average equity | -186.32% | - |
| Employees | 15 |
No comments:
Post a Comment